12:28:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 Ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 Ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 Ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2024-02-02 14:38:14

CS MEDICA received its third-issued patent on its "Wound Gel," offering an advanced healing process for wounds such as minor abrasions, cuts, burns, and sunburns.

CS MEDICA A/S ("CS MEDICA" or "The Company"), an innovator in the healthcare industry, is proud to announce the recent patent approval for its Wound Gel, marked by the Danish Patent and Trademark Office under patent number DK 181458. 

This achievement is the third patent granted to CS MEDICA in the past year, reinforcing the company's commitment to innovation in healthcare. Moreover, the company has advanced its research and development efforts with several more patent-pending treatments currently under review.

CS MEDICA specializes in developing accessible, effective, and clinically tested healthcare products with fewer side effects, targeting pain management and skin care categories. The CANNASEN® Wound Gel represents an essential advancement in the company's product portfolio, specifically designed to facilitate an optimal healing process of wounds such as minor abrasions, cuts, burns, and sunburns.

Lone Henriksen, CEO and founder of CS MEDICA states, "The approval of this patent, our third within a year, is a commitment to our focused approach towards healthcare innovation. Importantly, we are progressing with several more treatments pending patent approval, validating our purpose to deliver innovative healthcare solutions to 2- and 4-legged patients globally."

Lone continues, "Being a first-mover combining science with the therapeutical benefits of cannabinoids, under strict compliance and regulatory rules holds challenges, but this is a recognition for us to continue focusing on providing efficient, over-the-counter alternative treatments to the market."

About the Wound Gel

The Wound Gel is a CE-marked substance-based medical device proven for its safety and effectiveness. Features include:
  • A unique, patented formula that promotes an advanced healing process.
  • Applicability across a broad user base (launched as Wound Gel in the CANNASEN® brand and as White Label solutions. Also available as Make-to-Order for aminal treatments).
  • Documentation affirming its efficacy as a medical device.

For more information on the Wound Gel and other products by CS MEDICA, please visit cannasen.com or cs-medica.com

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-02-2024 14:38 CET.